Literature DB >> 33285036

Cleaning the dose falloff in lung SBRT plan.

Dharmin Desai1, Ganesh Narayanasamy2, Milan Bimali3, Ivan Cordrey1, Hisham Elasmar1, Senthamizhchelvan Srinivasan1, Ellis Lee Johnson4.   

Abstract

PURPOSE: To investigate a planning technique that can possibly reduce low-to-intermediate dose spillage (measured by R50%, D2cm values) in lung SBRT plans.
MATERIALS AND METHODS: Dose falloff outside the target was studied retrospectively in 102 SBRT VMAT plans of lung tumor. Plans having R50% and/or D2cm higher than recommended tolerances in RTOG protocols 0813 and 0915 were replanned with new optimization constraints using novel shell structures and novel constraints. Violations in the RTOG R50% value can be rectified with a dose constraint to a novel shell structure ("OptiForR50"). The construction of structure OptiForR50% and the novel optimization criteria translate the RTOG goals for R50% into direct inputs for the optimizer. Violations in the D2cm can be rectified using constraints on a 0.5 cm thick shell structure with inner surface 2cm from the PTV surface. Wilcoxon signed-rank test was used to compare differences in dose conformity, volume of hot spots, R50%, D2cm of the target in addition to the OAR doses. A two-sided P-value of 0.05 was used to assess statistical significance.
RESULTS: Among 102 lung SBRT plans with PTV sizes ranging from 5 to 179 cc, 32 plans with violations in R50% or D2cm were reoptimized. The mean reduction in R50% (4.68 vs 3.89) and D2cm (56.49 vs 52.51) was statistically significant both having P < 0.01. Target conformity index, volume of 105% isodose contour outside PTV, normal lung V20, and mean dose to heart and aorta were significantly lowered with P < 0.05.
CONCLUSION: The novel planning methodology using multiple shells including the novel OptiForR50 shell with precisely calculated dimensions and optimizer constraints lead to significantly lower values of R50% and D2cm and lower dose spillage in lung SBRT plans. All plans were successfully brought into the zone of no RTOG violations.
© 2020 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.

Entities:  

Keywords:  dose falloff; dose gradient; dose spill; lung SBRT; normal tissue toxicity

Mesh:

Year:  2020        PMID: 33285036      PMCID: PMC7856511          DOI: 10.1002/acm2.13113

Source DB:  PubMed          Journal:  J Appl Clin Med Phys        ISSN: 1526-9914            Impact factor:   2.102


  30 in total

1.  Spine stereotactic body radiation therapy plans: Achieving dose coverage, conformity, and dose falloff.

Authors:  Linda X Hong; Viswanathan Shankar; Jin Shen; Hsiang-Chi Kuo; Dinesh Mynampati; Ravindra Yaparpalvi; Lee Goddard; Amar Basavatia; Jana Fox; Madhur Garg; Shalom Kalnicki; Wolfgang A Tomé
Journal:  Med Dosim       Date:  2014-12-11       Impact factor: 1.482

Review 2.  Frontiers in planning optimization for lung SBRT.

Authors:  Francesca Romana Giglioli; Stefania Clemente; Marco Esposito; Christian Fiandra; Carmelo Marino; Serenella Russo; Lidia Strigari; Elena Villaggi; Michele Stasi; Pietro Mancosu
Journal:  Phys Med       Date:  2017-05-26       Impact factor: 2.685

3.  Dosimetric impact of breathing motion in lung stereotactic body radiotherapy treatment using intensity modulated radiotherapy and volumetric modulated arc therapy [corrected].

Authors:  Min Rao; Jianzhou Wu; Daliang Cao; Tony Wong; Vivek Mehta; David Shepard; Jinsong Ye
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-24       Impact factor: 7.038

4.  Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.

Authors:  Ryan Baker; Gang Han; Siriporn Sarangkasiri; MaryLou DeMarco; Carolyn Turke; Craig W Stevens; Thomas J Dilling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-08-25       Impact factor: 7.038

5.  4π noncoplanar stereotactic body radiation therapy for centrally located or larger lung tumors.

Authors:  Peng Dong; Percy Lee; Dan Ruan; Troy Long; Edwin Romeijn; Daniel A Low; Patrick Kupelian; John Abraham; Yingli Yang; Ke Sheng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-03-21       Impact factor: 7.038

Review 6.  Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.

Authors:  Puneeth Iyengar; Kenneth Westover; Robert D Timmerman
Journal:  Semin Respir Crit Care Med       Date:  2013-11-20       Impact factor: 3.119

7.  Quantifying interfraction and intrafraction tumor motion in lung stereotactic body radiotherapy using respiration-correlated cone beam computed tomography.

Authors:  Jean-Pierre Bissonnette; Kevin N Franks; Thomas G Purdie; Douglas J Moseley; Jan-Jakob Sonke; David A Jaffray; Laura A Dawson; Andrea Bezjak
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-22       Impact factor: 7.038

8.  A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927).

Authors:  Gregory M M Videtic; Chen Hu; Anurag K Singh; Joe Y Chang; William Parker; Kenneth R Olivier; Steven E Schild; Ritsuko Komaki; James J Urbanic; Robert D Timmerman; Hak Choy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-07-17       Impact factor: 7.038

9.  Lung Stereotactic Body Radiation Therapy (SBRT) dose gradient and PTV volume: a retrospective multi-center analysis.

Authors:  David Hoffman; Irena Dragojević; Jeremy Hoisak; David Hoopes; Ryan Manger
Journal:  Radiat Oncol       Date:  2019-09-03       Impact factor: 3.481

10.  A Dose Falloff Gradient Study in RapidArc Planning of Lung Stereotactic Body Radiation Therapy.

Authors:  Ganesh Narayanasamy; Dharmin Desai; Sanjay Maraboyina; Jose Penagaricano; Robert Zwicker; Ellis Lee Johnson
Journal:  J Med Phys       Date:  2018 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.